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Abstract
Purpose of review Women with suspected acute coronary syn-
drome are less likely to undergo investigation or receive treat-
ment than men, and women consistently have poorer outcomes.
This review summarises how the latest development in cardiac
biomarkers could improve both diagnosis and outcomes in
women.
Recent findings Novel high-sensitivity cardiac troponin assays
have identified differences in the reference range and therefore
diagnostic threshold for myocardial infarction in men and wom-
en. These differences are present across multiple populations
with different ethnic backgrounds and for a range of assays.
The use of a uniform threshold for cardiac troponin does not
provide equivalent prediction in men and women, with lower
thresholds needed for women to provide comparable risk
stratification.
Summary Sex differences in cardiac troponin concentrations
are not widely recognised in clinical practice and may be
contributing to the under-diagnosis of myocardial infarction
in women and discrepancies in patient care and outcomes.
Keywords Sex . Cardiac troponin . Biomarkers .Myocardial
infarction
Introduction
In September 2000, the United Nations Millennium Declaration
committed to promote gender equality as one of their primary
goals to achieve health equity. Globally, coronary heart disease
remains the major cause of death in women in both high-and
low- or middle-income nations [1]. Despite this, sex differences
remain in multiple aspects of cardiovascular care including diag-
nosis, access to investigation and treatment and outcomes [2••].
Furthermore, these differences are prevalent even in highly de-
veloped health-care systems such as the USA [2••, 3]. The most
recent scientific statement from the American Heart Association
(AHA) highlights two key areas that contribute to sex differ-
ences: biological or social factors, and the underrepresentation
of women in clinical trials [4].
Cardiovascular medicine is fortunate to have a high-quality
evidence base derived from multiple randomised control trials to
guide our practice. However, a comprehensive summary by
Nanette Wenger highlights how medical research has neglected
the health needs of women especially in cardiovascular medicine
[2••, 4]. Whilst improvements have been made to increase re-
cruitment of women in clinical trials, to date, large randomised
control trials include a majority of men. As such, the evidence on
safety and efficacy of key therapeutic interventions in acutemyo-
cardial infarction are limited in women with data largely derived
from their male counterparts.
More concerning is the evidence from epidemiological
studies and randomised controlled trials of disparities in out-
comes following myocardial infarction in men and women [3,
5]. The AHA scientific statement on myocardial infarction in
women highlighted this issue [4]. In data derived from large
multi-centred randomised control trials, women consistently
have higher case fatality rates compared to men, and these
differences exist despite adjusting for age and comorbid con-
ditions (Fig. 1a). Indeed, it is in the younger age groups that
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women are more likely than men to have an adverse event
following myocardial infarction (Fig. 1b). In a consecutive
series of over a million patients with acute coronary syn-
drome, even women <45 years were at increased risk of death
compared to men of a similar age (relative risk [RR] 1.3 [95%
confidence interval 1.2 to 1.4]) [3]. It is less clear what bio-
logical or social factors are responsible for these disparities.
Many have been proposed, including sex differences in the
pathobiology of acute myocardial infarction, in the time taken
to seek medical advice following the onset of symptoms and
in the efficacy of treatment for myocardial infarction. There
may also be differences in the presenting symptomology be-
tween men and women, which may result in misdiagnosis,
delay in providing evidence-based therapy and explain the
worse outcomes seen in women.
An alternative explanation, and one that is gaining increas-
ing attention, is that we are under-diagnosing myocardial in-
farction in women by not recognizing that there are important
differences in the reference range and diagnostic threshold of
cardiac biomarkers between men and women.
Diagnosis of Myocardial Infarction
The diagnosis of myocardial infarction is based on symptoms
or signs of myocardial ischaemia and biomarker evidence of
myocardial necrosis. The definition is largely unchanged from
the initial MONICAWorld Health Organization (WHO) state-
ment. What has, however, changed significantly over the last
few decades is our ability to detect and quantify myocardial
necrosis. The aim of the original WHO definition was to stan-
dardise diagnosis and permit monitoring of trends and deter-
minants of myocardial infarction in epidemiological studies.
This definition was not considered sufficiently specific in clin-
ical practice for the assessment of individual patients and was
open to interpretation [10]. The need for a more precise defi-
nition of myocardial infarction coupled with the availability of
more sensitive and specific biomarkers of myocardial necrosis
resulted in a series of consensus statements and revisions of
the definition of myocardial infarction.
Serum biomarkers have been used to assist in the diagnosis
of acute myocardial infarction for over half a century with
aspartate transaminases in the 1950s and lactate dehydroge-
nase in the 1970s [11]. However, it was not until the late 1970s
when an isoenzyme of creatine kinase (CK-MB) was discov-
ered that a biomarker revolutionised the clinical diagnosis of
myocardial infarction. In 2003, Apple et al. evaluated seven
CK-MB mass assays in 696 healthy participants, demonstrat-
ing that the 99th centile upper reference limit was two to
threefold higher in men [12]. As such, the National
Academy of Clinical Biochemistry guidelines advocated the
use of sex-specific 99th centile upper reference limits when
using CK-MB with a class 1C recommendation [13].
Cardiac Troponins
Troponin is a 3-piece regulatory protein complex present in
cardiac and skeletal muscle and is integral to muscle contrac-
tion. Both cardiac troponin T and troponin I are derived from
genes specific to the myocardium [14, 15], whereas troponin
C is present in both cardiac and skeletal muscles with no
specific isoform for cardiac tissue [14].
Given the high specificity of cardiac troponin T and tropo-
nin I to the myocardium, quantification of these biomarkers
has now become integral to the diagnosis of myocardial in-
farction. The latest consensus statement defines myocardial
infarction as a rise and/or fall in cardiac troponin with at least
one value above the 99th centile upper reference limit in the
context of symptoms or clinical evidence of myocardial is-
chaemia [16]. This was a paradigm shift replacing CK-MB
as the gold standard for the diagnosis of myocardial infarction.
Over the last decade, troponin assays have become increas-
ingly sensitive, from the older generation conventional assays
to the more sensitive contemporary troponin assays. The latest
developments in assay technology have led to the increasing
use of high-sensitivity troponin assays. These assays have
been defined as high-sensitivity by the International
Federation of Clinical Chemistry Task Force based on assay
performance [17]. A high-sensitive assay should meet two
basic criteria: first, the total coefficient of variation (a measure
of [im]precision) should be ≤10% at the 99th centile of a
healthy reference population and, second, at least 50% (and
ideally 90%) of the reference population should have a mea-
surable troponin concentration above the limit of detection.
Sex Differences in Cardiac Troponin Concentrations
The older generation cardiac troponin assays had initially been
thought to be good gender-independent markers for diagnosis in
acute coronary syndrome. Key papers published in the last two
decades challenged this view. In the 1990s, Hamm et al. mea-
sured cardiac troponin T inmen andwomenwith unstable angina
in whom acute myocardial infarction was excluded. The study
showed that troponin T concentrations were measurable
(>200 ng/L) in 43% of men and only 27% of women [18].
This initial observation was supported by Wiviott et al. who
demonstrated that in patients with unstable angina or non-ST
segment elevation myocardial infarction pooled from four
randomised control trials, men were more likely to have elevated
cardiac biomarkers including cardiac troponin I, cardiac troponin
T and CK-MB compared to women using older generation as-
says with a single diagnostic threshold [19].
More recently, developments in assay technology have greatly
enhanced sensitivity and, for the first time, have been able to
quantify circulating troponin in the majority of individuals in a
normal healthy reference population [20]. Measuring troponin
using high-sensitivity assays has revealed important differences
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between men and women, with the 99th centile reference limits
up to two-fold higher in men [20]. This observation has been
consistent across all troponin assays that have been evaluated and
has now been reported in multiple populations from different
ethnic backgrounds (Table 1). Indeed, the reference range has
been studied for 19 different assays in the same population, dem-
onstrating higher 99th centile upper reference limits for the two
clinically available high-sensitivity assays: cardiac troponin T
(20 ng/L men, 13 ng/L women) and cardiac troponin I (36 ng/
L men, 15 ng/L women) [20].
The mechanisms through which cardiac troponin is re-
leased into the circulation in the apparent ‘healthy’ state is
unclear, but may reflect cardiomyocyte apoptosis and cell
turnover, hypertrophy or sub-clinical myocardial fibrosis
[29, 30]. Furthermore, it is unclear why there is a difference
in the distribution of cardiac troponin concentrations in men
Fig. 1 Risk of mortality in
women compared to men in
randomised control trials before
and after adjustment for age (a)
and stratified by age in a large
cohort study (b). TIMI II
Thrombolysis in myocardial
infarction II [6], GUSTO Global
Utilization of t-PA and
Streptokinase for Occluded
Coronary Arteries (GUSTO-I)
trial [7], TAMI Thrombolysis and
Angioplasty in Myocardial
Infarction [8], ISIS-3 Third
International Study of Infarct
Survival [9]
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and women [31], but multiple hypotheses have been proposed
(Fig. 2) [29, 32, 33]. In contrast, sex differences in CK-MB
concentrations were attributed to differences in skeletal mass,
which contributes 1–2% of circulating CK-MB [31] and is
likely to explain higher levels in men. This is not the case
for cardiac troponin, which has excellent tissue specificity,
and therefore differences in the reference limits are likely to
reflect differences in cardiovascular physiology or the preva-
lence of sub-clinical pathology in men and women.
Likewise, in acute coronary syndrome, women have lower
cardiac troponin concentrations than men, perhaps suggesting
differences in the mechanism of myocardial infarction between
sexes. For example, in women with acute coronary syndrome
enrolled in the TACTICS-TIMI 18 trial, the odds of having an
elevated plasma cardiac troponin Tor I concentrations were 0.53
[95% CI 0.43 to 0.68]) and 0.58 [95% CI 0.46 to 0.73], respec-
tively, compared tomen [19]. Changes in reproductive hormones
during the menstrual cycle, pregnancy and menopause influence
both vasomotor function and endogenous fibrinolysis [34].
Perhaps, as a consequence, women with acute coronary syn-
drome are less likely to have evidence of plaque rupture (6.6
versus 16.3%; P=0.002) on intravascular coronary imaging
studies [35]. Indeed, women are more likely than men to have
non-obstructive atherosclerotic disease with either demonstrable
vasospasm, spontaneous coronary artery dissection or plaque
erosion with microembolization [36]; all of which are likely to
result in less myocardial injury and lower cardiac biomarker
concentrations.
Should We Apply Sex-Specific Thresholds
for the Diagnosis of Myocardial Infarction?
Both inconvenience and a potential source of confusion for
clinicians have been used as arguments against the use of sex-
specific thresholds [37]. However, sex-specific reference
ranges are not unfamiliar in clinical medicine and clinicians
have coped with such scenarios for decades. Common labo-
ratory parameters, including haemoglobin and glomerular fil-
tration rate, account for sex when determining reference
limits. Traditionally, clinical decision limits adjusted for sex
have been solely based on reference range studies [12], but
given the critical role of cardiac troponins in the diagnosis of
myocardial infarction, additional evidence is required from
outcome studies and from studies that evaluate diagnostic ac-
curacy of sex-specific thresholds.
Sex Differences in Troponin and Cardiovascular
Outcomes
Recently, a number of studies have evaluated differences in
the prognostic utility of high-sensitivity cardiac troponin be-
tweenmen and women in stable populations. The Activity and
Function in the Elderly study showed that in 1506 participantsTa
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over the age of 65 years, increasing cardiac troponin T and
troponin I concentrations were strongly associated with all-
cause mortality. These association varied by sex with women
having numerically higher age-adjusted associations with
mortality per unit increment in cardiac troponin (log-
transformed) compared to men for both troponin T (RR 3.67
[95% confidence interval (CI) 2.31 to 5.81] versus 2.15 [95%
CI 1.61 to 2.87]) and troponin I (3.33 [95% CI 2.13 to 5.18]
versus 1.92 [95% CI 1.55 to 2.38]) [38]. Similar associations
were echoed in the larger HUNT study with 9712 participants
including 5281 (54%) women. Increasing high-sensitivity car-
diac troponin I concentrations were associated with all-cause
mortality (RR 1.17 [95% CI 1.12 to 1.22] per 1 SD increment
in log troponin) and cardiovascular death (1.23 [95% CI 1.15
to 1.31]). Again, these associations were significantly and
numerically higher in women compared to men for both all-
cause mortality (1.33 [95% CI 1.24 to 1.42] versus 1.08 [1.01
to 1.15]) and cardiovascular death (1.44 [95%CI 1.31 to 1.58]
versus 1.10 [1.00 to 1.20], p value for interaction <0.001) [39].
Eggers et al. observed numerically higher associations be-
tween high-sensitivity cardiac troponin I and death or incident
cardiovascular disease in women compared to men in 1004
(502 women) elderly persons; however, sex was not a signif-
icant effect modifier for either [40].
These studies have important implications for clinical prac-
tice in guiding whether to adopt sex-specific thresholds for
cardiac troponin. One of the key obstacles, to date, has been
the lack of evidence that troponin concentrations above and
below sex-specific cut points infer different prognostic infor-
mation to that of single thresholds. Indeed, if higher troponin
levels do infer worse prognosis for women, as some of the
larger cohort studies seem to suggest, adopting single troponin
thresholds is likely to misclassify some women as low risk
with potentially important clinical ramifications.
Sex Differences in the Diagnosis of Myocardial Infarction
Whilst the Universal Definition of Myocardial Infarction ac-
knowledges that sex-specific differences exist in the upper
reference limits for these assays, no firm recommendations
for practice were made in the latest iteration [41]. Since the
publication of this guideline, several studies have evaluated
the impact of sex-specific thresholds using high-sensitivity
assays on the diagnosis of myocardial infarction (Table 2)
[42••, 43, 44, 46, 47, 48••].
In a prospective cohort of selected patients with suspected
acute coronary syndrome, Mueller-Hennessen et al. reported that
age-specific rather than sex-specific thresholds influenced the
diagnosis of myocardial infarction using the high-sensitivity car-
diac troponin T assay. Across 1282 patients (477 [37%] women)
with suspected acute coronary syndrome evaluated using a high-
sensitivity troponin T assay, the use of sex-specific compared to
uniform thresholds changed the rates of myocardial infarction
from 16 to 22% in women and from 23 to 21% in males.
However, the use of sex-specific thresholds had minimal impact
on risk stratification for death at 1 or 3 months [45]. However,
Rubini-Gimenez et al., in 2734 patients (876 [32%] women), did
not observe any effect of sex-specific thresholds on the diagnosis
of myocardial infarction and concluded that a uniform threshold
should remain standard of care for the high-sensitivity cardiac
troponin T assay [46].
In contrast, two studies have shown that women with
suspected acute coronary syndrome identified by the high-
sensitivity cardiac troponin I assay with sex-specific thresh-
olds, but missed with uniform thresholds, are at higher risk of
major adverse cardiac events (MACE) at 1 year [42••, 48••].
Cullen et al. demonstrate in a multi-centre cohort study of
2841 patients that MACE was increased in women with tro-
ponin concentrations above the sex-specific diagnostic
Fig. 2 Proposed biological
explanations for differences in the
distribution of cardiac troponin in
men and women
Curr Cardiol Rep (2017) 19: 40 Page 5 of 10 40
T
ab
le
2
St
ud
ie
s
ev
al
ua
tin
g
th
e
im
pa
ct
of
se
x-
sp
ec
if
ic
th
re
sh
ol
ds
fo
r
ca
rd
ia
c
tr
op
on
in
on
th
e
di
ag
no
si
s
of
m
yo
ca
rd
ia
li
nf
ar
ct
io
n
A
ut
ho
r
an
d
ye
ar
N
um
be
r
R
eg
io
n
Po
pu
la
tio
n
F
em
al
e
C
on
se
cu
tiv
e
pa
tie
nt
s
St
ud
y
as
sa
y
S
ex
-s
pe
ci
fi
c
th
re
sh
ol
ds
us
ed
C
om
m
en
ts
S
ha
h
et
al
.[
42
••
]
1,
12
6
Sc
ot
la
nd
Su
sp
ec
te
d
A
C
S
50
4
(4
5%
)
Y
es
H
ig
h
se
ns
iti
vi
ty
(A
bb
ot
tT
nI
)
M
:3
4,
F:
16
Se
x-
sp
ec
if
ic
th
re
sh
ol
ds
us
in
g
hi
gh
-s
en
si
tiv
ity
as
sa
ys
do
ub
le
d
th
e
di
ag
no
si
s
of
m
yo
ca
rd
ia
li
nf
ar
ct
io
n
in
w
om
en
C
ul
le
n
et
al
.[
43
]
28
41
A
us
tr
al
ia
an
d
N
ew
Z
ea
la
nd
C
he
st
pa
in
10
77
(3
8%
)
N
o
H
ig
h
se
ns
iti
vi
ty
(A
bb
ot
tT
nI
)
M
:3
4,
F:
16
Se
x-
sp
ec
if
ic
th
re
sh
ol
ds
id
en
tif
ie
d
w
om
en
bu
tn
ot
m
en
at
hi
gh
ri
sk
of
M
A
C
E
at
1
ye
ar
S
ch
of
er
et
al
.[
44
]
15
60
G
er
m
an
y
C
he
st
pa
in
54
1
(3
5%
)
N
o
H
ig
h
se
ns
iti
vi
ty
(S
in
gu
le
x
T
nI
)
M
:3
6,
F:
30
St
ud
y
sh
ow
ed
th
at
us
in
g
se
x-
sp
ec
if
ic
th
re
sh
ol
ds
w
ith
ab
so
lu
te
ch
an
ge
s
in
T
nI
co
nc
en
tr
at
io
ns
pe
rf
or
m
ed
be
tte
r
th
an
th
os
e
w
ith
re
la
tiv
e
ch
an
ge
s
M
ue
lle
r-
H
en
ne
ss
en
et
al
.[
45
]
12
82
E
ur
op
e,
m
ul
ti-
ce
nt
re
Su
sp
ec
te
d
A
C
S
47
7
(3
7%
)
N
o
H
ig
h
se
ns
iti
vi
ty
(R
oc
he
T
nT
)
M
:1
6;
F:
9
In
cr
ea
se
in
th
e
di
ag
no
si
s
of
m
yo
ca
rd
ia
li
nf
ar
ct
io
n
in
w
om
en
fr
om
16
to
23
%
bu
t
sm
al
lr
ed
uc
tio
n
in
th
e
pr
op
or
tio
n
of
m
al
es
di
ag
no
se
d
fr
om
23
to
21
%
G
im
en
ez
et
al
.[
46
]
27
34
E
ur
op
e,
m
ul
ti-
ce
nt
re
Su
sp
ec
te
d
A
C
S
87
6
(3
2%
)
N
o
H
ig
h
se
ns
iti
vi
ty
(R
oc
he
T
nT
)
M
:1
6;
F:
9
S
ex
-s
pe
ci
fi
c
th
re
sh
ol
ds
us
in
g
hi
gh
-s
en
si
tiv
ity
as
sa
ys
di
d
no
t
im
pr
ov
e
di
ag
no
si
s
of
m
yo
ca
rd
ia
li
nf
ar
ct
io
n
40 Page 6 of 10 Curr Cardiol Rep (2017) 19: 40
threshold, but below the uniform threshold, and that this as-
sociation persisted following adjustment for age. Similar find-
ings were reported in a consecutive cohort of 1126 patients
with suspected acute coronary syndrome from a single site in
Scotland [42••]. This study showed that the use of sex-specific
thresholds almost doubled the diagnosis of myocardial infarc-
tion in women when compared to a contemporary assay using
a uniform threshold.
Finally, it is important to note that there were marked dif-
ferences in the proportion of women recruited into these co-
hort studies, and therefore, it is likely that selection bias by
gender explains some of the discrepancies observed. The pro-
portion of women included in selected patient cohorts varied
from 32 to 38%, but in consecutive patient cohorts, where
selection bias is minimised, the proportion of women was
higher at 45% (Table 2).
Methodological Limitations of Studies Evaluating
Sex-Specific Thresholds
Unfortunately, the interpretation of diagnostic accuracy studies
using high-sensitivity cardiac troponins is challenging. Cardiac
troponin is integral to the diagnosis of myocardial infarction, and
there is no independent gold standard test to define spontaneous
or type 1 myocardial infarction, i.e. myocardial infarction due to
plaque rupture and coronary thrombosis [49]. As such, claims
that a more sensitive troponin test, whether using uniform or sex-
specific thresholds, is better than the reference test may be
contested [49, 50••]. The results of these studies are highly influ-
enced by choice of the reference test used to adjudicate the diag-
nosis. Furthermore, there are important differences between the
patients recruited into these cohort studies and those in whom
testing is performed in clinical practice. Troponin testing is per-
formed widely in patients attending the Emergency Department,
where clinicians are required to rapidly evaluate and exclude
multiple potential diagnosis simultaneously. The performance
of high-sensitivity cardiac troponin testing is likely to differ here
compared to selected patients presenting with symptoms of
suspected acute coronary syndrome alone.Women are less likely
to be recruited as they are thought to present with less typical
symptoms and are older and more likely to have comorbid con-
ditions. As such, selection bias will influence the generalisability
of the findings from diagnostic accuracy studies. Due to these
limitations, any review of studies comparing diagnostic perfor-
mance of uniform and sex-specific thresholds requires careful
attention to methodology.
When evaluating the use of more sensitive tests and cut
points that are lower than those measurable by previous tests,
the new test detects additional cases of apparent disease. There
will always be uncertainty as to whether those patients iden-
tified by the new test should be classified or treated in the
same way: Are these additional patients really true positives?
This is particularly relevant when retrospectively evaluating
the use of sex-specific thresholds as the 99th centile upper
reference limit in women is below the uniform threshold used
to guide further investigation at the time of presentation. In
contrast, in men, the sex-specific 99th centile upper reference
limit is higher than the uniform threshold. As such, women
identified retrospectively as having elevated cardiac troponin
concentrations only when sex-specific thresholds are applied
often did not undergo further diagnostic investigations at the
time of presentation to inform diagnostic adjudication.
Furthermore, women are under-represented in these cohort
studies as, unlike their male counterparts, they were less likely
to be identified as having an acute coronary syndrome at the
time of their presentation.
Glasziou et al. propose an elegant way of addressing this
issue: the use of an ‘umpire test’ [50••]. They suggest a three-
step process. First, investigators need to highlight cases,
which are discordant and identified only by one of the tests.
Second, they propose the use of an independent and fair test
that is unconditional to either of the tests being evaluated: the
umpire test. Third, these ‘umpire tests’ can include a multitude
of variables including causal exposures, outcomes and treat-
ment responses [50••]. For example, evidence of myocardial
ischaemia on electrocardiography could be used as such an
umpire test, where the discrepant group with a higher preva-
lence of ischaemia would indicate the superior test.
We adapted this methodology in our cohort of patients with
suspected acute coronary syndrome [42••]. The analysis
showed that those women newly identified as having myocar-
dial infarction using sex-specific thresholds had baseline char-
acteristics, risk factor profiles and prognoses similar to those
patients identified as having myocardial infarction using a uni-
form threshold, and that they were distinct from those identified
as not having myocardial infarction using both approaches.
Based on a logistic regression model, we showed that those
patients reclassified using sex-specific thresholds followed a
similar probability distribution and clinical trajectory to those
patients classified as myocardial infarction using the uniform
threshold [42••]. Importantly, this analysis was conducted in a
cohort that included all consecutive patients without selection
bias, and therefore, a similar proportion of men and women
were evaluated. We conclude that sex-specific thresholds for
high-sensitivity cardiac troponin I identify a significant propor-
tion of women missed using uniform thresholds and that these
women have other clinical features ofmyocardial infarction and
are at high risk of recurrent events.
Implementation and Clinical Practice
Lowering the diagnostic threshold following implementation
of a more sensitive troponin assay has been shown to improve
clinical outcomes [51••]. There was a halving of recurrent
myocardial infarction and death in those patients with small
previously unrecognised increases in cardiac troponin
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concentration. These improvements in outcome were associ-
ated with better patient care including more specialist refer-
rals, investigations and better provision of evidenced-based
therapies [51••]. These observations highlight the importance
that clinicians place on an abnormal troponin measurement in
guiding clinical decisions and suggest that high-sensitivity
troponin assays with even lower diagnostic thresholds have
the potential to improve care further.
However, progressively lowering the threshold of plasma tro-
ponin concentration in order to define increasing numbers of
patients withmyocardial infarction is likely to increase sensitivity
at the expense of reduced specificity [52]. Elevated cardiac tro-
ponin is common in patients without acute coronary syndrome
and accounts for up to 30% of all patients with troponin concen-
trations above the upper reference limit [53, 54]. Furthermore,
lowering the diagnostic threshold for cardiac troponin dispropor-
tionately increases the detection of patients with elevated cardiac
troponin levels in patients without acute coronary syndrome.
Outcomes of these patients remain poor after implementation
and does not appear to be modifiable [55]. High-sensitivity car-
diac troponin assays are likely to increase the frequency of tro-
ponin elevations in non-acute coronary syndrome pathologies
especially in women if sex-specific thresholds are employed. In
women, the proportion with troponin elevations due to non-acute
coronary syndrome pathologies increased from 7 to 12%, mov-
ing from a less sensitive contemporary troponin assay to a high-
sensitivity assay with sex-specific thresholds [42••].Whether im-
plementation of high-sensitivity cardiac troponin assays and use
of sex-specific diagnostic thresholds improve outcomes through
better targeting of treatments for coronary heart disease are the
focus of an ongoing multi-centre randomised control trial (clini-
cal trials.gov NCT01852123).
Conclusion
The evidence for and against the use of sex-specific thresholds
when implementing high-sensitivity cardiac troponin assays is
evolving. There are three main arguments in favour of adopting
sex-specific thresholds. First, cardiac troponin concentrations are
consistently lower in women than men, across multiple popula-
tions from different ethnic backgrounds. Second, cardiac tropo-
nin concentrations in stable populations infer different prognostic
information in men and women with stronger associations no-
ticed in women when uniform thresholds are applied. It is clear
that lower thresholds are needed for women to provide compa-
rable risk stratification. Third, in the setting of suspected acute
coronary syndrome, sex-specific thresholds for cardiac troponin I
identify women at high risk of future myocardial infarction and
death. Finally, it is recognised that women are less likely to
receive evidence-based therapy and have worse outcomes in
acute coronary syndromes. The use of sex-specific diagnostic
criteria may help to address these inequalities. Given these
discrepancies in the quality of care provided formen andwomen,
it seems axiomatic that sex-specific criteria be employed in the
diagnosis of myocardial infarction.
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